publication date: Feb. 28, 2014


Van Andel Institute to Build Epigenetics Hub

THE VAN ANDEL INSTITUTE announced the establishment of a global epigenetics research hub.

Leading this effort is Peter Jones, director of research and chief scientific officer of the institute. Jones’s recent research has focused on epigenetics and epigenetic therapies.

Jones’ plan includes developing a consortium of five academic institutions, four in the U.S. and one abroad, and is currently recruiting researchers and developing a clinical program.

was named the winner of the Lurie Prize in the Biomedical Sciences by the Foundation for the NIH.

Doudna is a professor of biochemistry, biophysics and structural biology at the University of California, Berkeley, and is a Howard Hughes Investigator. She will be presented the medal and a $100,000 honorarium on May 20 in Washington, D.C. Doudna’s work centers on the molecular structure of RNA.

Doudna, who is also a grantee of the National Institutes of Health and the National Science Foundation, was selected for the award by a jury of six distinguished biomedical researchers, working under the auspices of FNIH, and chaired by Solomon H. Snyder, M.D., Director-Emeritus of The Solomon H. Snyder Department of Neuroscience at Johns Hopkins University.

Doudna and her colleagues discovered a gene-editing technique called CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats. The technology “gives researchers the equivalent of a molecular surgery kit for routinely disabling, activating or changing genes,” wrote Science magazine in a Dec. 2013 article naming CRISPR one of its runners-up for breakthrough of the year.

received a commitment of $6 million from the Masters Tournament and Augusta National Golf Club through the Community Foundation for the Central Savannah … Continue reading 40-09 In Brief

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.